ABT . NYSE - Abbott Laboratories

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company's Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as various forms of prepared infant and follow-on formula. The company's Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, such as cataract surgery, LASIK surgery, and contact lens care and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices, and government agencies. It has strategic alliance with Fonterra Co-operative Group Ltd. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.


Análise Técnica:



A cotação encontra-se a tocar na linha de tendência ascendente. Espera-se uma correcção de curto prazo para a média móvel de 21 dias.

Análise Fundamental:


PER forward - 22
PER industria - 66,8



Considerando uma quebra de vendas e o PER da industria o modelo económico é favorável.


Considerando o forward PER e revenue a manter-se constante o modelo económico é desfavorável.



Recomendação:

Espera-se uma correcção quando a cotação bater na resistência da linha de tendencia ascendente. Possivel posição short.

Ocorreu uma ligeira correcção á média móvel, e a cotação encontra-se a acompanhar a linha de tendência de subida que é uma resistência de longo prazo.

Abbott Looking To Electrophysiology For Medical Device Growth
Nov. 27, 2014 7:41 AM ET |
Summary

Abbott Laboratories recently expanded its medical device business and entered the fast-growing catheter-based electrophysiology market with the acquisition of Topera, Inc.
The company also secured the right to buy Advanced Cardiac Therapeutics, a startup working on developing a novel ablation catheter.
Abbott’s interest in the electrophysiology market signals the company’s focus on turning around its ailing medical device business, which is significantly impacting its overall top line growth.

Abbott Laboratories (NYSE:ABT) recently expanded its medical device business and entered the fast-growing catheter-based electrophysiology market with the acquisition of Topera, Inc. Last month, Abbott entered into an agreement to buy the medical device company for $250 million, plus other potential performance-based payments in the future. The deal is expected to close by the end of the fourth quarter. Apart from Topera, the company also secured the right to buy Advanced Cardiac Therapeutics (ACT), a startup working on developing a novel ablation catheter. Heading Abbott's electrophysiology business will be Michael Pederson, former President and CEO of private medical device company VytronUS. Prior to that, he was also Vice President and General Manager of Boston Scientific's (NYSE:BSX) electrophysiology business.

Abbott's interest in the electrophysiology market signals the company's focus on turning around its ailing medical device business, which is significantly impacting its overall top line growth. Operational sales in the medical device division reported negative growth in the first nine months of 2014 year-over-year (y-o-y), compared to a growth of 3.9% in company-wide sales in the same period. Excluding the medical device business, Abbott's operational sales grew 5.3% y-o-y.

The global catheter-based electrophysiology market is expected to grow in double digits to about $3 billion by 2020. There is significant scope for growth in this business for Abbott, but it is also likely to face intense competition from existing players, including General Electric (NYSE:GE), Medtronic (NYSE:MDT), Boston Scientific, and Johnson & Johnson (NYSE:JNJ).

Topera's System And Technology

Topera has developed an innovative technology, including a diagnostic catheter and mapping software, to help improve diagnosis and treatment of atrial fibrillation. Atrial fibrillation (irregular heartbeat) is one of the most common cardiovascular conditions affecting almost 3 million people in the U.S. and 20 million worldwide. Its prevalence increases with age and it is estimated that the number of people diagnosed with atrial fibrillation in the U.S. will double in the next 30-40 years.

Topera's newest generation of 3D-mapping system was cleared by the FDA earlier this year and it helps identify rotors (associated with atrial fibrillation) using a color-imaging module. Abbott reported that a study on the use of Topera's system with catheter ablation suggested that patients had a success rate of 87.5% for the first ablation procedure, with a 80.5% success rate after one year. In comparison, catheter ablation alone has a success rate of only 50%-60%.

The Global Electrophysiology Market

The global electrophysiology market, comprising of ablation catheters, diagnostic catheters and lab systems, was valued at $1.56 billion in 2013 and is estimated to grow to about $3 billion by 2020, according to research firm GlobalData. Of this, advanced diagnostic catheters and standard ablation catheters are expected to grow to $1.2 billion and $575 million, respectively. This growth is likely to be fueled by an expanding geriatric population base, growing prevalence of atrial fibrillation in the population, and increased penetration of diagnostic and ablation catheters in developing markets such as Asia and South America.

Tal como previsto a cotação tocou na linha de tendencia ascendente (resistencia) e corrigiu á media movel, encontrando-se a corrigir a media movel de 50 dias.


VER NOTICIA AQUI
Abbott completes acquisition of Russian drug maker
Dec 12 2014, 12:22 ET | About: Abbott Laboratories (ABT) | By: Douglas W. House, SA News Editor [Contact this editor with comments or a news tip]

Abbott Laboratories (ABT -0.7%) finalizes its takeout of Russian pharmaceutical firm Veropharm. It acquired control of the company via its purchase of the holding company, Limited Liability Company Garden Hills, that owned ~98% of Veropharm, for 16.7B rubles (~$305M).
Previously: Abbott to buy Russian pharma company (June 23, 2014)

Encontra-se num canal de tendencia ascendente.
O price target do modelo de avaliação futuro é quase o dobro, pelo que ou a empresa esta tremendamente subvalorizada ou o modelo foi mal aplicado.
Por isso iremos analisa-la com mais cuidado no futuro.

Apresenta resultados a 29 de Janeiro.

O modelo depende muito do PER a utilizar.

De acordo com análise técnica a cotação encontra-se na linha do canal ascendente perto de uma resistencia de curto prazo.

Análise Fundamental:

Considerando o PER da indústria de 45,8 teremos o seguinte modelo de avaliação: